DEALS
Zhong Lun Advises Lifetech Scientific (Shenzhen) Co., Ltd. on HK GEM Board IPO
Zhong Lun Advises Lifetech Scientific (Shenzhen) Co., Ltd. on HK GEM Board IPO
Zhong Lun Law Firm has recently advised Lifetech Scientific (Shenzhen) Co., Ltd. on its initial public offering (IPO) and placing on the Growth Enterprise Market (GEM) Board of the Hong Kong stock exchange. Trading of its shares began on November 10, 2011. Piper Jaffray Asia Limited was the sponsor, and Piper Jaffray Asia Securities Limited was the Lead Manager and Bookrunner.
LifeTech Scientific is a developer, manufacturer and marketer of advanced minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The group is the second largest provider worldwide of congenital heart defect (CHD) occluders with about 19% market share in terms of the number of CHD occluder implantation procedures conducted. It currently has distributors in 26 countries across Asia, Europe, South America, North America and Africa reaching over 1,450 hospitals.